This is a working overview of Photo-oxidation, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-14 and is reviewed periodically as new material appears.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Pyruvate, the product of glycolysis under aerobic conditions, is a metabolic branch point. As a preliminary to following the central path of aerobic metabolism from glycolysis to the citric acid cycle, we put pyruvate in perspective by considering its various possible fates. We also consider the broader context of common carboxylation and decarboxylation reactions in biochemistry.
A nuclear isomer is a metastable state of an atomic nucleus in which one or more nucleons (protons or neutrons) occupy excited state levels (higher energy levels). "Metastable" describes nuclei whose excited states have half-lives of 10−9 seconds or longer, 100 to 1000 times longer than the half-lives of the excited nuclear states that decay with a "prompt" half-life (ordinarily on the order of 10−12 seconds). Some references recommend using a threshold of 5×10−9 seconds to distinguish the metastable half-life from the normal "prompt" gamma-emission half-life. The half-lives of a number of isomers are far longer than this and may be minutes, hours, or years. The most extreme example known is the 180m73Ta nuclear isomer, which survives so long (at least 2.9×1017 years) that it has never been observed to decay spontaneously, and occurs naturally as a primordial nuclide, though uncommonly at only 1/8000 of all tantalum. The second most stable isomer is 210m83Bi, which does not occur naturally; its half-life is 3.04×106 years to alpha decay. The half-life of a nuclear isomer can exceed that of the ground state of the same nuclide, as with the two above, as well as, for example, 186m75Re, 192m277Ir, 212m84Po, 242m95Am and multiple holmium isomers.
== Function == Following binding of GnRH, the GnRHR associates with G-proteins that activate a phosphatidylinositol (PtdIns)-calcium second messenger system. Activation of the GnRHR ultimately causes the release of follicle stimulating hormone (FSH) and luteinizing hormone (LH).
Bully: Wes Victim(s): Chris Fighter: Tony Bonello Money earned by Bully: $6,000 (but turned down $5,000 from the 2nd round; left with $1,000). Money earned by victim(s): $4,000 (but the Bully let him keep the $5,000 from Round 2, left with $9,000). Original airing:
Sources: en.wikipedia.org
==== Companion of the Order of the Bath (CB) ==== Military Division Royal Navy Major General Simon James Pack, . Surgeon Vice Admiral Anthony Leslie Revell, . Army Major General Jeremy Joseph Julian Phipps (472598), late The Queen's Own Hussars. Major General Michael Ian Eldon Scott, . (467628), late Scots Guards. Major General Michael Alan Willcocks (476673), late Royal Regiment of Artillery. Royal Air Force Air Vice-Marshal Geoffrey Wellesley Carleton. Air Vice Marshal Terence Brian Sherrington, . Civil Division Elizabeth Ann Chant, Chief Executive, Child Support Agency, Department of Social Security. George Michael Devereau, lately Chief Executive, Central Office of Information. David James Essery, Head of Group 1, Home Department, Scottish Office. David Gibson. For public service. Brian Richard Hawtin, lately Assistant Under Secretary (Home & Overseas), Ministry of Defence. David Alan Hogg, Deputy Treasury Solicitor, Treasury Solicitor's Department. James McQuaid, Chief Scientist, Health and Safety Executive, Department of the Environment. Arthur John Pryor, lately Head, Competition Policy Division, Department of Trade and Industry. Stephen Arthur Robson, Director, Finance Regulation and Industry Directorate, Her Majesty's Treasury. Terence Anthony Rochester, Chief Highway Engineer, the Highways Agency, Department of Transport. Professor Clive Harrod Smee, Chief Economic Adviser and Director of Operational Research, Department of Health. Christopher Camplin Wilcock, lately Head, Nuclear Power Privatisation Team, Department of Trade and Industry.
Naram-Sin, also transcribed Narām-Sîn or Naram-Suen (Akkadian: 𒀭𒈾𒊏𒄠𒀭𒂗𒍪: DNa-ra-am DSîn, meaning "Beloved of the Moon God Sîn", the "𒀭" a determinative marking the name of a god; died c. 2218 BC), was a ruler of the Akkad, who reigned c. 2255–2218 BC (middle chronology), and was the third successor and grandson of King Sargon of Akkad. Under Naram-Sin, the kingdom reached its maximum extent. He was the first Mesopotamian king known to have claimed divinity for himself, taking the title "God of Akkad", and the first to claim the title "King of the Four Quarters". His military strength was strong as he crushed revolts and expanded the kingdom to places like Turkey and Iran. He became the patron city god of Akkade as Enlil was in Nippur. His enduring fame resulted in later rulers, Naram-Sin of Eshnunna and Naram-Sin of Assyria as well as Naram-Sin of Uruk, assuming the name.
The author has attenuated Natrum muriaticum (common table-salt) until there was not a single saline property left ... and yet, with one drop of that attenuation in a goblet of water, and a teaspoonful of the water administered at intervals of three hours, she has cured a patient sinking in the last stage of typhoid fever. The highest attenuation of homœopathy and the most potent rises above matter into mind. This discovery leads to more light. From it may be learned that either human faith or the divine Mind is the healer and that there is no efficacy in a drug. She argued that even naming and reading about disease could turn thoughts into physical symptoms, and that the recording of ages might reduce the human lifespan. To explain how individuals could be harmed by poison without holding beliefs about it, she referred to the power of majority opinion. Eddy allowed exceptions from Christian Science prayer, including for dentistry, optometry and broken limbs; she said she had healed broken bones using "mental surgery," but that this skill would be the last to be learned. But for the most part (then and now), Christian Scientists believe that medicine and Christian Science are incompatible. Medicine asserts that something needs to be fixed, while Christian Science asserts that spiritual reality is perfect and beliefs to the contrary need to be corrected. In the 1890s Richard Cabot of Harvard Medical School studied the healing testimonies published by the Christian Science Journal, which Eddy founded in 1883, for his senior thesis.
=== Andy Harris === Andy Harris is Jackie and Fred's son, born in 1994 on the episode "Labor Day". Jackie breastfeeds Andy at the altar while marrying Fred ("Altar Egos"). Andy was the ringbearer at Darlene and David's wedding ("The Wedding"). Jackie occasionally dressed him in outfits Fred deemed to be feminine. D.J. made it a point to spend time with Andy because they were the only younger males in the family until Jerry's birth. Cousins Andy and Jerry took naps together in the same crib when they were babies. Andy has been retconned out of existence in The Conners, with producer Bruce Helford explaining that the new show's producers have chosen to deliberately ignore certain developments of later seasons of Roseanne—including Andy's birth.
{\displaystyle {\begin{aligned}{\cfrac {V_{\max }}{1+{\cfrac {\ce {[I]}}{K_{i}}}}}&={V_{\max }}\left({\cfrac {K_{i}}{K_{i}+[{\ce {I}}]}}\right)&&{\text{multiply by }}{\cfrac {K_{i}}{K_{i}}}=1\\&={V_{\max }}\left({\cfrac {K_{i}+[{\ce {I}}]-[{\ce {I}}]}{K_{i}+[{\ce {I}}]}}\right)&&{\text{add }}[{\ce {I}}]-[{\ce {I}}]=0{\text{ to numerator}}\\&={V_{\max }}\left(1-{\cfrac {[{\ce {I}}]}{K_{i}+[{\ce {I}}]}}\right)&&{\text{simplify }}{\cfrac {K_{i}+[{\ce {I}}]}{K_{i}+[{\ce {I}}]}}=1\\&=V_{\max }-V_{\max }{\cfrac {\ce {[I]}}{K_{i}+[{\ce {I}}]}}&&{\text{multiply out by }}V_{\max }\end{aligned}}}
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
RP-HPLC is widely used for purity and impurity profiling. Mass spectrometry confirms identity.